Pregnancy outcome following first-trimester exposure to fingolimod: A collaborative ENTIS study.

Details

Ressource 1Request a copy Under indefinite embargo.
UNIL restricted access
State: Public
Version: Final published version
License: Not specified
Serval ID
serval:BIB_2D36E32A728F
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Pregnancy outcome following first-trimester exposure to fingolimod: A collaborative ENTIS study.
Journal
Multiple sclerosis
Author(s)
Pauliat E., Onken M., Weber-Schoendorfer C., Rousson V., Addor M.C., Baud D., Théaudin M., Diav-Citrin O., Cottin J., Agusti A., Rollason V., Kaplan Y.C., Kennedy D., Kadioglu M., Rothuizen L.E., Livio F., Buclin T., Panchaud A., Winterfeld U.
ISSN
1477-0970 (Electronic)
ISSN-L
1352-4585
Publication state
Published
Issued date
03/2021
Peer-reviewed
Oui
Volume
27
Number
3
Pages
475-478
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
This prospective multicentre cohort study investigated pregnancy outcomes after fingolimod use for multiple sclerosis during pregnancy. Pregnancy outcomes of 63 fingolimod and 62 interferon-β-exposed pregnancies were compared. Rates of major congenital anomalies (MCA) were 4.8% (2/42) in the fingolimod group versus 2.3% (1/44) in the interferon-β group (odds ratio, 2.2; 95% confidence interval, 0.2-24.6). The adjusted hazard ratio for spontaneous abortion in fingolimod versus interferon-β-exposed pregnancies was 0.6 (95% confidence interval, 0.2-1.8). Further studies are needed to definitely rule out a moderately increased MCA risk after fingolimod exposure during pregnancy.
Keywords
Fingolimod, birth defect, cohort study, interferon, multiple sclerosis, pregnancy
Pubmed
Web of science
Create date
25/06/2020 14:27
Last modification date
29/09/2023 5:57
Usage data